Potenciális antitumor hatású FGFR inhibitorok fejlesztése.

Translated title of the contribution: [Developing FGFR inhibitors as potential anti-cancer agents].

Lilian Zsákai, Gábor Németh, Csaba Szántai-Kis, Zoltán Greff, Zoltán Horváth, Bálint Szokol, Ferenc Baska, Tin Chuad Boon, L. Őrfi, G. Kéri

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Fibroblast Growth Factor Receptor (FGFR) family is a sequentially highly related subgroup of membrane proteins consisting of four tyrosine kinase type enzyme: FGFR1, FGFR2, FGFR3 and FGFR4. These are kinases of great interest in a wide spectrum of physiological processes such as tissue repair via controlling cell proliferation. As initiatiors of cell proliferation, in some cases they have leading roles in several types of cancer, eg. breast cancer, pancreas cancer, gastric tumors and multiple myeloma via overexpression and/or mutation. This phenomenon makes them promising targets for drug development in order to develop signal transduction therapies based on small molecule FGFR inhibitors. We have developed two main groups of lead molecules: compounds with benzotiophene and oxindole cores utilizing numerous methods from in silico modelling via in vitro biochemichal assays and testing on relevant cell lines to cytotoxicity assays.

Original languageHungarian
Pages (from-to)47-56
Number of pages10
JournalActa Pharmaceutica Hungarica
Volume83
Issue number2
Publication statusPublished - 2013

Fingerprint

Fibroblast Growth Factor Receptors
Pancreatic Neoplasms
Cell Proliferation
Receptor, Fibroblast Growth Factor, Type 1
Physiological Phenomena
Multiple Myeloma
Computer Simulation
Stomach Neoplasms
Signal Transduction
Neoplasms
Membrane Proteins
Phosphotransferases
Breast Neoplasms
Cell Line
Mutation
Enzymes
Pharmaceutical Preparations
Therapeutics
Lead
oxindole

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Zsákai, L., Németh, G., Szántai-Kis, C., Greff, Z., Horváth, Z., Szokol, B., ... Kéri, G. (2013). Potenciális antitumor hatású FGFR inhibitorok fejlesztése. Acta Pharmaceutica Hungarica, 83(2), 47-56.

Potenciális antitumor hatású FGFR inhibitorok fejlesztése. / Zsákai, Lilian; Németh, Gábor; Szántai-Kis, Csaba; Greff, Zoltán; Horváth, Zoltán; Szokol, Bálint; Baska, Ferenc; Boon, Tin Chuad; Őrfi, L.; Kéri, G.

In: Acta Pharmaceutica Hungarica, Vol. 83, No. 2, 2013, p. 47-56.

Research output: Contribution to journalArticle

Zsákai, L, Németh, G, Szántai-Kis, C, Greff, Z, Horváth, Z, Szokol, B, Baska, F, Boon, TC, Őrfi, L & Kéri, G 2013, 'Potenciális antitumor hatású FGFR inhibitorok fejlesztése.', Acta Pharmaceutica Hungarica, vol. 83, no. 2, pp. 47-56.
Zsákai L, Németh G, Szántai-Kis C, Greff Z, Horváth Z, Szokol B et al. Potenciális antitumor hatású FGFR inhibitorok fejlesztése. Acta Pharmaceutica Hungarica. 2013;83(2):47-56.
Zsákai, Lilian ; Németh, Gábor ; Szántai-Kis, Csaba ; Greff, Zoltán ; Horváth, Zoltán ; Szokol, Bálint ; Baska, Ferenc ; Boon, Tin Chuad ; Őrfi, L. ; Kéri, G. / Potenciális antitumor hatású FGFR inhibitorok fejlesztése. In: Acta Pharmaceutica Hungarica. 2013 ; Vol. 83, No. 2. pp. 47-56.
@article{8e40e93e6b0b403a8b5e3ea2339efd44,
title = "Potenci{\'a}lis antitumor hat{\'a}s{\'u} FGFR inhibitorok fejleszt{\'e}se.",
abstract = "Fibroblast Growth Factor Receptor (FGFR) family is a sequentially highly related subgroup of membrane proteins consisting of four tyrosine kinase type enzyme: FGFR1, FGFR2, FGFR3 and FGFR4. These are kinases of great interest in a wide spectrum of physiological processes such as tissue repair via controlling cell proliferation. As initiatiors of cell proliferation, in some cases they have leading roles in several types of cancer, eg. breast cancer, pancreas cancer, gastric tumors and multiple myeloma via overexpression and/or mutation. This phenomenon makes them promising targets for drug development in order to develop signal transduction therapies based on small molecule FGFR inhibitors. We have developed two main groups of lead molecules: compounds with benzotiophene and oxindole cores utilizing numerous methods from in silico modelling via in vitro biochemichal assays and testing on relevant cell lines to cytotoxicity assays.",
author = "Lilian Zs{\'a}kai and G{\'a}bor N{\'e}meth and Csaba Sz{\'a}ntai-Kis and Zolt{\'a}n Greff and Zolt{\'a}n Horv{\'a}th and B{\'a}lint Szokol and Ferenc Baska and Boon, {Tin Chuad} and L. Őrfi and G. K{\'e}ri",
year = "2013",
language = "Hungarian",
volume = "83",
pages = "47--56",
journal = "Acta Pharmaceutica Hungarica",
issn = "0001-6659",
publisher = "Magyar Gyogyszereszeti Tarsasag",
number = "2",

}

TY - JOUR

T1 - Potenciális antitumor hatású FGFR inhibitorok fejlesztése.

AU - Zsákai, Lilian

AU - Németh, Gábor

AU - Szántai-Kis, Csaba

AU - Greff, Zoltán

AU - Horváth, Zoltán

AU - Szokol, Bálint

AU - Baska, Ferenc

AU - Boon, Tin Chuad

AU - Őrfi, L.

AU - Kéri, G.

PY - 2013

Y1 - 2013

N2 - Fibroblast Growth Factor Receptor (FGFR) family is a sequentially highly related subgroup of membrane proteins consisting of four tyrosine kinase type enzyme: FGFR1, FGFR2, FGFR3 and FGFR4. These are kinases of great interest in a wide spectrum of physiological processes such as tissue repair via controlling cell proliferation. As initiatiors of cell proliferation, in some cases they have leading roles in several types of cancer, eg. breast cancer, pancreas cancer, gastric tumors and multiple myeloma via overexpression and/or mutation. This phenomenon makes them promising targets for drug development in order to develop signal transduction therapies based on small molecule FGFR inhibitors. We have developed two main groups of lead molecules: compounds with benzotiophene and oxindole cores utilizing numerous methods from in silico modelling via in vitro biochemichal assays and testing on relevant cell lines to cytotoxicity assays.

AB - Fibroblast Growth Factor Receptor (FGFR) family is a sequentially highly related subgroup of membrane proteins consisting of four tyrosine kinase type enzyme: FGFR1, FGFR2, FGFR3 and FGFR4. These are kinases of great interest in a wide spectrum of physiological processes such as tissue repair via controlling cell proliferation. As initiatiors of cell proliferation, in some cases they have leading roles in several types of cancer, eg. breast cancer, pancreas cancer, gastric tumors and multiple myeloma via overexpression and/or mutation. This phenomenon makes them promising targets for drug development in order to develop signal transduction therapies based on small molecule FGFR inhibitors. We have developed two main groups of lead molecules: compounds with benzotiophene and oxindole cores utilizing numerous methods from in silico modelling via in vitro biochemichal assays and testing on relevant cell lines to cytotoxicity assays.

UR - http://www.scopus.com/inward/record.url?scp=84886237797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886237797&partnerID=8YFLogxK

M3 - Article

C2 - 23926649

AN - SCOPUS:84886237797

VL - 83

SP - 47

EP - 56

JO - Acta Pharmaceutica Hungarica

JF - Acta Pharmaceutica Hungarica

SN - 0001-6659

IS - 2

ER -